伏诺拉生与枳术宽中胶囊联合应用对胃食管反流病患者预后的疗效及对HO-1、GSH表达水平的影响  

Prognosis and Efficacy of Vonoprazan Combined with Zhizhu Kuanzhong Capsule in the Treatment of Patients with Gastroesophageal Reflux Disease and Its Effects on Expression Levels of HO-1 and GSH

作　　者：田燕 孙晶 杨长青[1] TIAN Yan;SUN Jing;YANG Changqing(Dept.of Gastroenterology,Heping Hospital Affiliated to Changzhi Medical College,Shanxi Changzhi 046000,China)

机构地区：[1]长治医学院附属和平医院消化内科,山西长治046000

出　　处：《中国医院用药评价与分析》2024年第11期1348-1351,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：山西省应用基础研究计划项目(No.202202B121024)。

摘　　要：目的:探讨伏诺拉生与枳术宽中胶囊联合应用对胃食管反流病(GERD)预后的疗效及对血清血红素氧合酶-1(HO-1)、谷胱甘肽(GSH)表达水平的影响。方法:纳入2022年5月1日至2023年5月1日该院收治的GERD患者120例,采用数字抽签分组方式分组。对照组(n=60)、观察组(n=60)患者分别采用伏诺拉生、伏诺拉生联合枳术宽中胶囊治疗。比较两组患者的疗效,HO-1、GSH表达水平,胃食管反流病问卷(GERDQ)评分、炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素(IL)1β和IL-6]水平及不良反应发生率。结果:观察组患者的治疗有效率为96.67%(58/60),高于对照组的81.67%(49/60),差异有统计学意义(P<0.05)。观察组与对照组患者治疗前血清指标(HO-1、GSH)、症状评分(GERDQ)和炎症因子(TNF-α、IL-1β、IL-6)的差异均无统计学意义(P>0.05)。治疗后,观察组患者的HO-1水平低于对照组,GSH水平高于对照组,GERDQ评分低于对照组,TNF-α、IL-1β和IL-6水平低于对照组,差异均有统计学意义(P<0.05)。观察组、对照组患者的不良反应发生率分别为5.00%(3/60)、6.67%(4/60),差异无统计学意义(P>0.05)。结论:伏诺拉生联合枳术宽中胶囊治疗胃食管反流病的临床疗效更佳,能显著改善GERD患者的实验室指标及临床症状,且用药安全性高。OBJECTIVE:To probe into the the prognosis and efficacy of vonoprazan combined with Zhizhu Kuanzhong capsule in the treatment of patients with gastroesophageal reflux disease(GERD)and its effects on expression levels of heme oxygenase-1(HO-1)and glutathione(GSH).METHODS:Totally 120 patients with GERD admitted into the hospital from May 1st,2022 to May 1st,2023 were extracted to be divided into two groups by digital lottery grouping method.The control group(n=60)and study group(n=60)respectively received vonoprazan and vonoprazan combined with Zhizhu Kuanzhong capsule.The efficacy,expression levels of HO-1 and GSH,gastroesophageal reflux disease questionnaire(GERDQ)score,inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin(IL)-1β,IL-6]levels and incidence of adverse drug reactions of two groups were compared.RESULTS:The effective rate of the study group was 96.67%(58/60),higher than 81.67%(49/60)of the control group,the difference was statistically significant(P<0.05).There was no significant difference in serum indexes(HO-1,GSH),symptom score(GERDQ)and inflammatory factors(TNF-α,IL-1β,IL-6)between two groups before treatment(P>0.05).After treatment,HO-1 in the study group was lower than that in the control group,GSH was higher than that in the control group,GERDQ score was lower than that in the control group,the levels of TNF-α,IL-1βand IL-6 were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse drug reactions in the study group and the control group was respectively 5.00%(3/60)and 6.67%(4/60),with no statistically significant difference(P>0.05).CONCLUSIONS:The clinical efficacy of vonoprazan combined with Zhizhu Kuanzhong capsule in the treatment of GERD is better,and the laboratory indicators and clinical symptoms of GERD can be significantly improved with higher safety.

关 键 词：伏诺拉生 枳术宽中胶囊 胃食管反流病 血红素氧合酶-1 谷胱甘肽 

分 类 号：R975[医药卫生—药品] R932[医药卫生—药学]